AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.13) per share. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.
ERYTECH Pharma Shares Down 34.7% After Co. Announced It Will Stop Further Plans To Pursue BLA Seeking Approval For Graspa In Hypersensitive ALL
ERYTECH to stop further plans to pursue a BLA submission seeking an approval for Graspa® in hypersensitive ALL
Evaluation of strategic partnering options ongoing
Cambridge, MA (U.S.) and Lyon (France),
